| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/13/2009 | CA2711932A1 Edible film-strips for immediate release of active ingredients |
| 08/13/2009 | CA2711413A1 Alendronate formulations, method of making and method of use thereof |
| 08/13/2009 | CA2711407A1 Aqueous dispersion containing polysaccharide particulate gel and method for producing the same |
| 08/13/2009 | CA2706812A1 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
| 08/13/2009 | CA2706505A1 Effervescent compositions |
| 08/13/2009 | CA2700182A1 Cyclosporin compositions |
| 08/12/2009 | EP2087912A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 08/12/2009 | EP2087909A1 Formulation of an injectable paracetamol solution, method of manufacturing and packaging such a solution and device for packaging such a solution |
| 08/12/2009 | EP2087904A1 Therapeutic use of peptides derived from Bcl-XL protein in cancer patients |
| 08/12/2009 | EP2087902A1 Oral formulations designed to protect the airways, with special reference to inflammatory and neoplastic symptoms |
| 08/12/2009 | EP2087893A1 Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and processes for preparing them |
| 08/12/2009 | EP2087890A1 Sustained release preparation for tissue regeneration therapy |
| 08/12/2009 | EP2087889A2 Controlled release oral tablet having a unitary core |
| 08/12/2009 | EP2087887A1 Highly absorbable composition for oral administration containing oxidized coenzyme q10 |
| 08/12/2009 | EP2087884A2 Extended Release Gliclazide Formulations |
| 08/12/2009 | EP2087883A1 Stabilised supersaturated solid solutions of steroidal drugs |
| 08/12/2009 | EP2087882A1 Drug microparticles |
| 08/12/2009 | EP2086641A2 Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders |
| 08/12/2009 | EP2086617A2 Phospholipid-based inhalation system |
| 08/12/2009 | EP2086589A2 Ultrasound microbubble mediated genes delivery system |
| 08/12/2009 | EP2086581A2 Stabilization of vaccines by lyophilization |
| 08/12/2009 | EP2086572A2 Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| 08/12/2009 | EP2086570A1 Use of beta-lactamase |
| 08/12/2009 | EP2086567A1 Sustained release formulations comprising very low molecular weight polymers |
| 08/12/2009 | EP2086550A2 Estrogen/ serm and estrogen/ progestin bi-layer tablets |
| 08/12/2009 | EP2086529A2 Antimicrobial compositions and related applications |
| 08/12/2009 | EP2086524A1 Transnasal anticonvulsive pharmaceutical composition |
| 08/12/2009 | EP2086523A2 Inhaler devices and bespoke pharmaceutical compositions |
| 08/12/2009 | EP2086522A2 Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement |
| 08/12/2009 | EP2086521A2 Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs |
| 08/12/2009 | EP2086520A1 Imatinib compositions |
| 08/12/2009 | EP2086519A1 Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| 08/12/2009 | EP2086518A2 Darusentan oral dosage form |
| 08/12/2009 | EP2086517A2 Pharmaceutical dosage form |
| 08/12/2009 | EP2086516A1 Melt-processed imatinib dosage form |
| 08/12/2009 | EP2086515A2 Rate-controlled bioadhesive oral dosage formulations |
| 08/12/2009 | EP2086514A2 Pharmaceutical compositions comprising an s1p modulator |
| 08/12/2009 | EP2086513A1 Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof |
| 08/12/2009 | EP2086512A2 Dry granulated pharmaceutical compositions and methods for producing same |
| 08/12/2009 | EP2086511A2 Polymer-based antimicrobial agents, methods of making said agents, and products and applications using said agents |
| 08/12/2009 | EP2086510A1 Preparation of a free flowing molecular dispersion of clopidogrel base |
| 08/12/2009 | EP2086509A1 Escitalopram and solid pharmaceutical composition comprising the same |
| 08/12/2009 | EP2086508A2 Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
| 08/12/2009 | EP2086507A1 A spinal nucleus pulposus implant |
| 08/12/2009 | EP2086506A2 Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy |
| 08/12/2009 | EP2086505A2 Injectable depot composition and its process of preparation |
| 08/12/2009 | EP2086504A2 Diclofenac gel |
| 08/12/2009 | EP2086503A2 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| 08/12/2009 | EP2086502A1 Punctal plug comprising a water-insoluble polymeric matrix |
| 08/12/2009 | EP2086501A2 A bleomycin preparation for use against skin tumours |
| 08/12/2009 | EP2086498A2 Eyelid scrub composition |
| 08/12/2009 | EP2086351A1 Edible emulsions with pgpr |
| 08/12/2009 | EP2086316A2 Subunguicide, and method for treating onychomycosis |
| 08/12/2009 | EP1978925B1 Thermosetting neutralized chitosan composition forming a hydrogel, lyophilizate, and processes for producing the same |
| 08/12/2009 | EP1720518B1 Alginate viscoelastic composition, method of use and package |
| 08/12/2009 | EP1635854A4 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 08/12/2009 | EP1601346B1 Method for producing a pharmaceutical composition in the form of fibrate-containing tablets and tablets produced by said method |
| 08/12/2009 | EP1592760A4 Solid dispersion compositions |
| 08/12/2009 | EP1496866B1 Process for preparing tannate liquid and semi-solid dosage forms |
| 08/12/2009 | EP1409645B1 Probiotic lactobacillus salivarius strains |
| 08/12/2009 | EP1401376A4 Colloidal metal compositions and methods |
| 08/12/2009 | EP1347753B3 Topical composition and method for treating urinary stress incontinence |
| 08/12/2009 | EP1175257B9 Spray drying apparatus and methods of use |
| 08/12/2009 | EP1032367B1 Fibrin sealants or adhesives comprising a hyaluronic acid derivative material |
| 08/12/2009 | CN101506266A Vaccine delivery compositions and methods of use |
| 08/12/2009 | CN101505818A Drug delivery device with piezoelectric actuator |
| 08/12/2009 | CN101505794A scFV antibodies which pass epithelial and/or endothelial layers |
| 08/12/2009 | CN101505789A A stable liquid formulation of human growth hormone |
| 08/12/2009 | CN101505773A Agent for treating eye diseases |
| 08/12/2009 | CN101505763A Modulation of the immune system by inositol phospholipids |
| 08/12/2009 | CN101505754A Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate |
| 08/12/2009 | CN101505750A Sugar-free storage-stable antihistaminic syrups |
| 08/12/2009 | CN101505738A Chewable tablet containing phenylephrine |
| 08/12/2009 | CN101505737A Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors |
| 08/12/2009 | CN101505736A Controlled release system and method for manufacturing the same |
| 08/12/2009 | CN101505735A Pharmaceutical compositions for sustained release of phenyephrine |
| 08/12/2009 | CN101505734A Process for preparing pramipexole dihydrochloride tablets with high storage stability |
| 08/12/2009 | CN101505733A Active agent formulations, methods of making, and methods of use |
| 08/12/2009 | CN101505732A Low dose sublingual tablets of opioid analgesics and preparation process |
| 08/12/2009 | CN101505731A Compositions comprising calcium citrate malate and methods for making the same |
| 08/12/2009 | CN101505730A Compositions comprising calcium citrate malate and methods for making the same |
| 08/12/2009 | CN101505729A Biocompatible polymer compounds for medicinal formulations |
| 08/12/2009 | CN101505728A Aerosol formulation containing beta agonists and steroids |
| 08/12/2009 | CN101505727A Pharmaceutical composition for oral administration |
| 08/12/2009 | CN101505726A Pharmaceutical suspensions comprising phenylephrine and method of preparation |
| 08/12/2009 | CN101505725A Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility |
| 08/12/2009 | CN101505724A Galenic formulations of aliskiren |
| 08/12/2009 | CN101505723A Collagen scaffolds, medical implants with same and methods of use |
| 08/12/2009 | CN101505722A Flowable carrier matrix |
| 08/12/2009 | CN101505714A Use of a composition for skin treatment under x-irradiation |
| 08/12/2009 | CN101505695A Punctal plugs for the delivery of active agents |
| 08/12/2009 | CN101505694A Punctal plugs for the delivery of active agents |
| 08/12/2009 | CN101505592A Patch for the expulsion of insect poison from the skin after stings from membranous insects (hymenoptera) |
| 08/12/2009 | CN101503662A Microbial strain for antianaphylaxis symptom, composition thereof and method for producing interferon-gamma by using the microbial strain irritation cell |
| 08/12/2009 | CN101503458A Small molecule polypeptide for preventing and treating angiogenesis and use thereof |
| 08/12/2009 | CN101503132A Patch package structure |
| 08/12/2009 | CN101502668A Polyphenol-protein complexes and method for producing the same, patch containing the polyphenol-protein complexes and method for producing the same |
| 08/12/2009 | CN101502655A Method for preparing pH-sensitive photocrosslinkable hydrogel |
| 08/12/2009 | CN101502654A Preparation method of high-gloss high-stability Elsinochrome silicon oxide nano granule and application thereof in preparing intravenous injection agent |
| 08/12/2009 | CN101502649A Liposome influenza vaccine |